Alivus Life Sciences has fixed Tuesday, September 1, 2026, as the record date for determining shareholder entitlement to the final dividend of ₹5 per equity share for the financial year ended March 31, 2026. This distribution, recommended by the Board of Directors on May 14, 2026, is contingent upon approval at the Fifteenth Annual General Meeting (AGM) scheduled for Tuesday, September 8, 2026. The dividend payment, if approved, will be made on or after Friday, September 11, 2026, subject to applicable tax deductions at source.

The company notified the Bombay Stock Exchange and the National Stock Exchange of India Ltd regarding the AGM and record date in compliance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The AGM will be conducted via Video Conferencing or Other Audio-Visual Means (OAVM) at 03:00 pm IST, adhering to circulars issued by the Ministry of Corporate Affairs and SEBI.

Dividend Entitlement and Payment Details

Shareholders holding equity shares of ₹2 each will be eligible for the dividend based on their holdings as of the close of business hours on the record date. The payment mechanism differs slightly for dematerialized and physical holdings:

The company emphasized that the dividend is subject to deduction of tax at source. For shareholders holding shares in dematerialized form, the entitlement is determined by the data provided by the depositories. For those holding physical shares, valid transmission or transposition requests must be processed by the record date.

Key Dates and Compliance

The timeline for the dividend process is structured around the AGM approval. The Board’s recommendation was made on May 14, 2026, establishing the proposed payout amount. The subsequent fixing of the record date on August 6, 2026, ensures that shareholders have clear visibility on eligibility criteria before the general meeting.

The Fifteenth AGM serves as the final approval mechanism for this financial distribution. Conducting the meeting through VC/OAVM aligns with current regulatory frameworks allowing remote participation. The company secretary and compliance officer, Rudalf Joseph Corriea, signed the intimation, confirming adherence to listing obligations.

What the Numbers Show

The declaration of a ₹5 per share final dividend represents a tangible return to shareholders for FY26. With the face value of the equity share standing at ₹2, the dividend yield calculation depends on the market price at the time of investment. The fixed record date of September 1, 2026, creates a definitive cutoff for ownership, ensuring that only those holding shares through that date receive the payout. This structure provides clarity for investors planning their positions ahead of the AGM on September 8, 2026.

Alivus Life Sciences Limited has made the audio recording of its Q1 FY27 earnings call available to investors, following the conference held on July 31, 2026. The company uploaded the recording to its official website to ensure transparency and accessibility for stakeholders, in adherence to regulatory disclosure norms. This procedural step complements the financial results announced earlier, which reported a record net profit of ₹1,601 million for the quarter ended June 30, 2026.

The upload was confirmed via a letter addressed to the Department of Corporate Services at BSE Ltd. and the Manager – Listing at National Stock Exchange of India Ltd., citing Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rudalf Corriea, Company Secretary & Compliance Officer, signed off on the communication on July 31, 2026, directing investors to the specific URL for access.

Regulatory Compliance and Access

The audio file is hosted at the company’s investor relations portal, providing detailed insights into management’s commentary on the Q1FY27 performance. The results highlighted a 31.8% year-on-year increase in profit after tax (PAT) and an expansion in EBITDA margins to 33.06% from 28.64%. The earnings call discussion likely covered these operational highlights, including the robust growth in the non-Generic Pharmaceutical Ingredient (non-GPL) portfolio, which grew 26.5% year-on-year.

Investors can access the recording directly through the provided link: https://alivus.b-cdn.net/alivus_pdfs/investors/financials/reports_presentation/10044984.mp3 . This ensures that all market participants have equal access to the management’s perspective on the financial health and future outlook of the company.

Financial Context

The availability of the earnings call audio adds depth to the previously reported financial figures. Key metrics from Q1FY27 include:

The company’s strong cash position of ₹8,802 million and free cash flow generation of ₹901 million during the quarter further underscore its financial stability. The earnings call serves as a critical channel for addressing investor queries regarding capacity expansion plans, including the Solapur, Ankleshwar, and Dahej facilities, and their expected completion timelines in FY27.